

Innovation Showcase

Revolutionising drug-delivery for women

Dr Janet Halliday




**Calla Lily
Clinical Care**



The problem

Current methods of drug-delivery for indications in fertility, pregnancy and a range of gynaecological conditions are profoundly inadequate for millions of women around the world.

Vaginal delivery has multiple medical benefits and can avoid the need for painful daily injections – but existing products are flawed and cause stress, uncertainty and inconvenience.



“Calla Lily has developed a new leak-free vaginal drug-delivery platform...”

Our solution: the Callavid® device

Patented drug-delivery platform enables clean and hygienic delivery of medicines and hormones, with core underlying tech cleared by US FDA

Folding mini-liner


sits between labia, absorbs excipients & increased bodily fluid discharge

Sheath

flexible & breathable,
hygienic insertion & removal

Scaffold

selectively absorbs aqueous bodily fluid discharge, but not the medication



Drug formulation

joined to tip, or coated onto scaffold
(dependent on excipients)

- Leakage protection
- Placement and dosage confidence
- Comfort and convenience
- Mess-free insertion and removal
- Reduced variability in drug absorption



The market opportunity

\$20bn⁺ potential through numerous use cases for our versatile platform


- **Fertility & Pregnancy:** Progesterone for IVF & Miscarriage
4 million pregnancies and 1 in 4 pregnancies end in miscarriage
- **Vaginal Microbiome:** Multi-strain live biotherapeutic (LBP) delivery for vaginal dysbiosis / Bacterial Vaginosis
250 million BV cases annually with high recurrence
- **Future Indications / Other drugs inc. Cancer & OTC medications:** e.g. Vaginal Candidiasis, Cervical Cancer, Vulvovaginal Atrophy, Haemorrhoids, etc.
- **Diagnostic Sample Collection:** e.g. Endometriosis detection tests reliant upon unique aspects of our device



Forecast revenue– drug-delivery platform

Success with progesterone delivery is the springboard for several further applications including vaginal microbiome & oncology

Licensing Income & Regional Rights Sales



Our team is passionate about women's health

LEADERSHIP

Thang Vo-Ta
co-founder & CEO



Ex Goldman Sachs IB/PE, *The Times*
Top 100 Entrepreneur, *The*
Manufacturer Top 20 Exemplar

Lara Zibners MD MMed MBA FAAP FACEP
co-founder & director



Royal College
of Surgeons
of England



UNC
KENAN-FLAGLER
BUSINESS SCHOOL

Pediatric ER doc, author,
patient-perspective IVF
experience

Professor Andrew Lewis PhD FREng
principal scientist



50+ patents, Ex Head of R&D /
Inventor at Biocompatibles/BTG
(acquired by Boston Scientific)

Akeel Khan MBA
chief product officer



Large-scale automation &
complex manufacturing
expertise

ADVISORS

Dr Stuart Lavery
Divisional Clinical Director
Women's Health /
Reproductive
Medicine (UCLH), Official
Spokesperson British Fertility
Society



Dr Kelle Moley
VP, Global Translational
and Clinical R&D; Head of
Reproductive Medicine &
Maternal Health – Ferring,
former Deputy Director of
Reproductive Health at the
Bill & Melinda Gates
Foundation



Dr Janet Halliday
Former Associate VP –
Ferring Controlled
Therapeutics & External
Technology



Professor Siobhan Quenby
Director Biomedical
Research Unit in
Reproductive Health,
Professor of Obstetrics Univ
of Warwick



Dr Annalisa Jenkins
Prior senior leadership roles
at Merck Serono, Bristol
Myers-Squibb, and
Dimension Therapeutics.
Board Director of
Oncimmune, AVROBIO,
COMPASS Pathways, Affimed
and Mereo Biopharma

